DIIs bought Rs 16,434 crore worth of shares and sold shares worth Rs 10,394 crore. Meanwhile, FIIs purchased Rs 14,753 crore in shares and offloaded equities worth Rs 20,437 during the trading session ...

The Signals Research Suite is the first fully integrated SaaS platform. This solution is ideal for scientists working on new drug modalities or who want to expand the power of Signals Notebook across ...

Shares of Lumos Pharma rallied after investment firm Double Point Ventures agreed to buy the biopharmaceutical company for $38 million in cash plus potential milestone payments. Lumos shares rose 12% ...

The future of health care starts on Jan. 20, 2025. The stakes for Americans could not be higher. Whether it’s Vice President Kamala Harris or former President Donald Trump in the White House that day, ...

The consignment of mephedrone worth Rs. 2.17 crores and 427.95 kilograms of semi processed mephedrone was seized by Surat and ...

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases.

Smart manufacturing is transforming pharmaceutical production, enhancing efficiency, quality control, and regulatory ...

The former headquarters of a collapsed developer in North Wales could become an apart-hotel under new plans. GM Jones built ...

Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains, highlighting the urgent ...

Shares of Lumos Pharma were set to rise after investment firm Double Point Ventures agreed to buy the biopharmaceutical company for $38 million in cash plus potential milestone payments.

In conclusion, a demerger, like any major pivot, is a high-stakes, high-value moment where everything matters. Reconnect to ...

A multi-omics approach to identify biomarkers of response to the novel and selective SRC/YES1 inhibitor NXP900 ...